ClinicalTrials.gg
Drug

Eltrombopag clinical trials

Also written Promacta, Revolade, SB497115 and ETB115.

studies test it
135
open now
14
in phase 3
25
first study started
2005

How each study uses eltrombopag is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the eltrombopag studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 Nov 2008 · PROMACTA · NDA 022291 (FDA, Drugs@FDA)
European Union
11 Mar 2010 · Revolade · EMEA/H/C/001110 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Eltrombopag
101
eltrombopag olamine
9
EPAG
3
Eltrombopag (EPAG)
2
Eltrombopag/Revolade
2

Brand

Promacta
25
Revolade
20

Development codes

SB497115
11
ETB115
9

Studies by the year they started

134 studies that test it; most in 2012 (13); 1 more planned to start later

Studies that test eltrombopag, by start year
YearStudies
20053
20065
20075
20083
200911
20108
20117
201213
201313
20148
20157
20164
20173
201810
20197
20209
20213
20223
20232
20242
20257
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
27
Phase 2
81
Phase 3
25
Phase 4
10
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 49 · Other 86

GlaxoSmithKline (29) · Novartis Pharmaceuticals (18) · National Heart, Lung, and Blood Institute (NHLBI) (7) · M.D. Anderson Cancer Center (6) · Institute of Hematology & Blood Diseases Hospital, China (3) · Assiut University (3) · Weill Medical College of Cornell University (3) · Associazione Qol-one (2)

Often tested with

Tested in the same studies.

Cyclosporine (5) · Romiplostim (3) · Diacerein (2) · Dexamethasone (2) · Rituximab (2) · Thymoglobulin (1) · Rosuvastatin (1) · Adagrasib (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test eltrombopag.

Studies

Open first, then newest update. How each study uses eltrombopag is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 135

See all 135 studies that test eltrombopag →

Given beside what is tested · 7 — eltrombopag is usual care or a partner of the new treatment
As the comparator · 4 — what is tested is compared with eltrombopag

Codes

What other systems call eltrombopag · ClinicalTrials.gg INT005109

  • MeSH (NLM) C520809eltrombopagConfirmed NLM, Wikidata
  • UNII (FDA) S56D65XJ9GELTROMBOPAGConfirmed FDA, NLM, Wikidata
  • RxNorm 711942Confirmed FDA, Wikidata
  • Wikidata Q411588eltrombopagConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C71634EltrombopagOne source FDA
  • DrugBank DB06210One source Wikidata

Also registered as eltrombopag olamine (UNII 4U07F515LG · RxNorm 735651).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.